Management of asthma in resource-limited settings: Role of low-cost corticosteroid/β-agonist combination inhaler

C. Y. Chiang, N. Aït-Khaled, K. Bissell, D. A. Enarson

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The management of asthma requires medicines that are effective in relaxing airway smooth muscles and in reducing airway inflammation. Rapid-acting β2 agonist is a bronchodilator that provides quick symptom relief in patients with asthma. However, it does not effectively address the underlying problem of airway inflammation. Excess use of inhaled bronchodilators alone for symptom relief may result in delay in seeking health care, which in turn may result in delayed use of anti-inflammatory agents. Inhaled corticosteroid (ICS) is critical in the treatment of airway inflammation; it reduces the risk of life-threatening asthma attacks and the need for hospitalisation. ICS is underused, however, and a substantial proportion of patients with persistent asthma in resource-limited settings have no access to affordable ICS for long-term treatment. International guidelines recommend the use of rapidacting β-agonists as needed as rescue treatment when symptoms occur. Studies have shown that the use of both ICS and rapid-acting β-agonist as needed for symptom relief might be a better option. The combination of ICS and rapid-acting bronchodilator in a single inhaler is currently too expensive and is not affordable for the poor. Although ICS and short-acting β2 agonist (SABA) for rescue treatment can be obtained to a certain extent by using separate ICS and SABA inhalers, the first step is to ensure access to affordable, quality-assured essential asthma medicine in resourcelimited settings.

Original languageEnglish
Pages (from-to)129-136
Number of pages8
JournalInternational Journal of Tuberculosis and Lung Disease
Volume19
Issue number2
DOIs
Publication statusPublished - Feb 1 2015

Fingerprint

Nebulizers and Vaporizers
Adrenal Cortex Hormones
Asthma
Costs and Cost Analysis
Bronchodilator Agents
Inflammation
Therapeutics
Smooth Muscle
Hospitalization
Anti-Inflammatory Agents
Medicine
Guidelines
Delivery of Health Care

Keywords

  • Access
  • Case management
  • Developing countries
  • Essential drugs

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Infectious Diseases

Cite this

Management of asthma in resource-limited settings : Role of low-cost corticosteroid/β-agonist combination inhaler. / Chiang, C. Y.; Aït-Khaled, N.; Bissell, K.; Enarson, D. A.

In: International Journal of Tuberculosis and Lung Disease, Vol. 19, No. 2, 01.02.2015, p. 129-136.

Research output: Contribution to journalArticle

@article{ae52643a84a04c629cbe7d036e6fc27e,
title = "Management of asthma in resource-limited settings: Role of low-cost corticosteroid/β-agonist combination inhaler",
abstract = "The management of asthma requires medicines that are effective in relaxing airway smooth muscles and in reducing airway inflammation. Rapid-acting β2 agonist is a bronchodilator that provides quick symptom relief in patients with asthma. However, it does not effectively address the underlying problem of airway inflammation. Excess use of inhaled bronchodilators alone for symptom relief may result in delay in seeking health care, which in turn may result in delayed use of anti-inflammatory agents. Inhaled corticosteroid (ICS) is critical in the treatment of airway inflammation; it reduces the risk of life-threatening asthma attacks and the need for hospitalisation. ICS is underused, however, and a substantial proportion of patients with persistent asthma in resource-limited settings have no access to affordable ICS for long-term treatment. International guidelines recommend the use of rapidacting β-agonists as needed as rescue treatment when symptoms occur. Studies have shown that the use of both ICS and rapid-acting β-agonist as needed for symptom relief might be a better option. The combination of ICS and rapid-acting bronchodilator in a single inhaler is currently too expensive and is not affordable for the poor. Although ICS and short-acting β2 agonist (SABA) for rescue treatment can be obtained to a certain extent by using separate ICS and SABA inhalers, the first step is to ensure access to affordable, quality-assured essential asthma medicine in resourcelimited settings.",
keywords = "Access, Case management, Developing countries, Essential drugs",
author = "Chiang, {C. Y.} and N. A{\"i}t-Khaled and K. Bissell and Enarson, {D. A.}",
year = "2015",
month = "2",
day = "1",
doi = "10.5588/ijtld.14.0363",
language = "English",
volume = "19",
pages = "129--136",
journal = "International Journal of Tuberculosis and Lung Disease",
issn = "1027-3719",
publisher = "International Union against Tubercul. and Lung Dis.",
number = "2",

}

TY - JOUR

T1 - Management of asthma in resource-limited settings

T2 - Role of low-cost corticosteroid/β-agonist combination inhaler

AU - Chiang, C. Y.

AU - Aït-Khaled, N.

AU - Bissell, K.

AU - Enarson, D. A.

PY - 2015/2/1

Y1 - 2015/2/1

N2 - The management of asthma requires medicines that are effective in relaxing airway smooth muscles and in reducing airway inflammation. Rapid-acting β2 agonist is a bronchodilator that provides quick symptom relief in patients with asthma. However, it does not effectively address the underlying problem of airway inflammation. Excess use of inhaled bronchodilators alone for symptom relief may result in delay in seeking health care, which in turn may result in delayed use of anti-inflammatory agents. Inhaled corticosteroid (ICS) is critical in the treatment of airway inflammation; it reduces the risk of life-threatening asthma attacks and the need for hospitalisation. ICS is underused, however, and a substantial proportion of patients with persistent asthma in resource-limited settings have no access to affordable ICS for long-term treatment. International guidelines recommend the use of rapidacting β-agonists as needed as rescue treatment when symptoms occur. Studies have shown that the use of both ICS and rapid-acting β-agonist as needed for symptom relief might be a better option. The combination of ICS and rapid-acting bronchodilator in a single inhaler is currently too expensive and is not affordable for the poor. Although ICS and short-acting β2 agonist (SABA) for rescue treatment can be obtained to a certain extent by using separate ICS and SABA inhalers, the first step is to ensure access to affordable, quality-assured essential asthma medicine in resourcelimited settings.

AB - The management of asthma requires medicines that are effective in relaxing airway smooth muscles and in reducing airway inflammation. Rapid-acting β2 agonist is a bronchodilator that provides quick symptom relief in patients with asthma. However, it does not effectively address the underlying problem of airway inflammation. Excess use of inhaled bronchodilators alone for symptom relief may result in delay in seeking health care, which in turn may result in delayed use of anti-inflammatory agents. Inhaled corticosteroid (ICS) is critical in the treatment of airway inflammation; it reduces the risk of life-threatening asthma attacks and the need for hospitalisation. ICS is underused, however, and a substantial proportion of patients with persistent asthma in resource-limited settings have no access to affordable ICS for long-term treatment. International guidelines recommend the use of rapidacting β-agonists as needed as rescue treatment when symptoms occur. Studies have shown that the use of both ICS and rapid-acting β-agonist as needed for symptom relief might be a better option. The combination of ICS and rapid-acting bronchodilator in a single inhaler is currently too expensive and is not affordable for the poor. Although ICS and short-acting β2 agonist (SABA) for rescue treatment can be obtained to a certain extent by using separate ICS and SABA inhalers, the first step is to ensure access to affordable, quality-assured essential asthma medicine in resourcelimited settings.

KW - Access

KW - Case management

KW - Developing countries

KW - Essential drugs

UR - http://www.scopus.com/inward/record.url?scp=84937121549&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937121549&partnerID=8YFLogxK

U2 - 10.5588/ijtld.14.0363

DO - 10.5588/ijtld.14.0363

M3 - Article

C2 - 25574908

AN - SCOPUS:84937121549

VL - 19

SP - 129

EP - 136

JO - International Journal of Tuberculosis and Lung Disease

JF - International Journal of Tuberculosis and Lung Disease

SN - 1027-3719

IS - 2

ER -